Shenouda Maged, CFO of Relmada Therapeutics ($RLMD), made five open market purchases of company shares worth $1.25 million over the past year. His most recent buy occurred on December 15, 2025. With no sales recorded, Maged ranks 425th out of nearly 5,000 insiders for purchase volume, below the $1.46 million average but above the typical 3.3 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 12, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | A | Stock Appreciation Rights | 828000 | $0.00 | 828,000.0000 | 33,191,622 | 9999.99% | 2.49% |
| Dec. 15, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 11665 | $4.12 | 800,000.0000 | 33,191,622 | 1.48% | 0.04% |
| Nov. 5, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 500000 | $2.20 | 788,335.0000 | 33,191,622 | 173.41% | 1.51% |
| June 26, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | A | Stock Option (right to buy) | 600000 | $0.00 | 600,000.0000 | 30,408,890 | 9999.99% | 1.97% |
| May 16, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 50000 | $0.44 | 138,335.0000 | 30,408,890 | 56.60% | 0.16% |
| May 19, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 90000 | $0.49 | 228,335.0000 | 30,408,890 | 65.06% | 0.30% |
| May 20, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 60000 | $0.52 | 288,335.0000 | 30,408,890 | 26.28% | 0.20% |
| Sept. 9, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 8194 | $2.55 | 43,097.0000 | 30,174,202 | 23.48% | 0.03% |
| Sept. 10, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 21118 | $2.73 | 64,215.0000 | 30,174,202 | 49.00% | 0.07% |
| Sept. 11, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 24120 | $2.95 | 88,335.0000 | 30,174,202 | 37.56% | 0.08% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | J | Stock Option (right to buy) | 54624 | $0.00 | 82,090.0000 | 30,132,170 | 39.95% | 0.18% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | A | Stock Option (right to buy) | 54624 | $0.00 | 136,714.0000 | 30,132,170 | 66.54% | 0.18% |
| Jan. 30, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 15000 | $3.89 | 28,028.0000 | 30,099,203 | 115.14% | 0.05% |
| Jan. 31, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 6875 | $4.06 | 34,903.0000 | 30,099,203 | 24.53% | 0.02% |
| Jan. 29, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Shenouda Maged | Chief Financial Officer | P | Common Stock | 10800 | $3.65 | 13,028.0000 | 30,099,203 | 484.74% | 0.04% |